Subscribe to our Newsletters !!
Like never seen before, coral reefs across the
High capacity and performance combined with an int
Dr. Mohammed Enayat’s recent testimony on his ag
It is with utmost pride that Microbioz India annou
The world of pharmaceuticals encompasses a broad s
For some time now,
In our cover story, we shine a spotlight on “ The Magazine
Pharma significant Lupin Limited (Lupin) declared the dispatch of approved nonexclusive adaptation of Bausch Health’s Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (approved nonexclusive form) are shown for the support of abatement of ulcerative colitis in patients 18 years old and more seasoned.
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso® had a yearly deals of around USD 290 million in the U.S. (IQVIA MAT March 2020).
Portions of LUPIN LTD. was last exchanging BSE at Rs.839.9 when contrasted with the past close of Rs. 857.1. The all out number of offers exchanged during the day was 101636 in more than 3469 exchanges.
The stock hit an intraday high of Rs. 869.9 and intraday low of 833.8. The net turnover during the day was Rs. 86690663.
